Endo International's Unit Launches Generic Version Of Valcyte - Quick Facts

(RTTNews) - Specialty healthcare company Endo International plc (ENDP) Thursday said its Qualitest unit has introduced a generic version of Hoffmann-La Roche, Inc.'s Valcyte or Valganciclovir Tablets USP, 450 mg, which is an antiviral medication used for treating cytomegalovirus infections.

Commenting on the launch, Rajiv De Silva, CEO of Endo said: "Our generic product, as the first generic version of Valcyte available in the U.S. plays an important role in providing patients with a more affordable treatment option."

According to IMS Health data, Valcyte had generated total U.S. sales of nearly $440 million, for the 12 months ended September 30, 2014.